Neuraxis (NRXS) Profit After Tax (2022 - 2025)
Neuraxis (NRXS) posted Profit After Tax of -$1.7 million for Q4 2025, up 19.51% sequentially from -$2.1 million in Q3 2025, and down 18.01% YoY from -$2.1 million in Q4 2024.
Neuraxis (NRXS) Profit After Tax (2022 - 2025) Analysis & Trends
Neuraxis has reported Profit After Tax for 4 years, with the latest figure at -$1.7 million in Q4 2025.
- Quarterly Profit After Tax fell 18.01% year-over-year to -$1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.8 million (up 5.35% YoY) and the FY2025 annual result came in at -$7.8 million, up 5.35% from the prior year.
- Profit After Tax climbed to -$1.7 million in Q4 2025 per NRXS's latest filing, from -$2.1 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$13628.0 in Q4 2022 and troughed at -$8.6 million in Q3 2023.
- A 4-year average of -$2.3 million and a median of -$2.1 million in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax plunged 11584.02% in 2023, then jumped 79.65% in 2024.
- Over 4 years, Profit After Tax stood at -$13628.0 in 2022, then slumped by 11584.02% to -$1.6 million in 2023, then rose by 9.07% to -$1.4 million in 2024, then fell by 18.01% to -$1.7 million in 2025.
- According to Business Quant data, Profit After Tax over the past three periods registered -$1.7 million, -$2.1 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.71 Mn |
| Sep 30, 2025 | -2.12 Mn |
| Jun 30, 2025 | -1.69 Mn |
| Mar 31, 2025 | -2.28 Mn |
| Dec 31, 2024 | -1.45 Mn |
| Sep 30, 2024 | -1.76 Mn |
| Jun 30, 2024 | -2.92 Mn |
| Mar 31, 2024 | -2.12 Mn |
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | -8.63 Mn |
| Jun 30, 2023 | -2.24 Mn |
| Mar 31, 2023 | -2.17 Mn |
| Dec 31, 2022 | -13,628.00 |
| Sep 30, 2022 | -2.08 Mn |
| Jun 30, 2022 | -1.52 Mn |